These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 18793546)

  • 1. A trial comparing local pain after subcutaneous injection of epoetin-beta versus darbepoetin-alpha in healthy volunteers.
    Berthoux F; Ryckelynck JP; Rouanet S; Gelu-Mantoulet S; Montestruc F; Mouchel P; Choukroun G;
    Clin Nephrol; 2008 Jul; 70(1):33-40. PubMed ID: 18793546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subcutaneous injection pain with C.E.R.A., a continuous erythropoietin receptor activator, compared with darbepoetin alfa.
    Pannier A; Jordan P; Dougherty FC; Bour F; Reigner B
    Curr Med Res Opin; 2007 Dec; 23(12):3025-32. PubMed ID: 17961301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased injection pain with darbepoetin-alpha compared to epoetin-beta in paediatric dialysis patients.
    Schmitt CP; Nau B; Brummer C; Rosenkranz J; Schaefer F
    Nephrol Dial Transplant; 2006 Dec; 21(12):3520-4. PubMed ID: 16935904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomised, cross-over study comparing injection site pain with subcutaneous epoetin beta and subcutaneous darbepoetin alfa in patients with chronic kidney disease.
    Roger SD; Suranyi MG; Walker RG; Disney A; Isbel NM; Kairaitis L; Pollock CA; Brown FG; Chow J; Truman MI; Ulyate KA;
    Curr Med Res Opin; 2008 Aug; 24(8):2181-7. PubMed ID: 18565240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pain at the injection site of subcutaneously administered erythropoietin: phosphate-buffered epoetin alpha compared to citrate-buffered epoetin alpha and epoetin beta.
    Veys N; Dhondt A; Lameire N
    Clin Nephrol; 1998 Jan; 49(1):41-4. PubMed ID: 9491285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of pain and efficacy of darbepoetin alfa and epoetin Beta pegol treatment in patients receiving peritoneal dialysis.
    Otsuka T; Sakai Y; Yui S; Sukegawa M; Suzuki A; Mugishima K; Sumi Y; Otsuka Y; Tsuruoka S
    J Nippon Med Sch; 2015; 82(1):21-6. PubMed ID: 25797871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Australian haemodialysis patients on intravenous epoetin alfa or intravenous darbepoetin alfa: how do they compare?
    Pussell BA; Walker R;
    Nephrology (Carlton); 2007 Apr; 12(2):126-9. PubMed ID: 17371333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Darbepoetin alpha in lower-than-equimolar doses maintains haemoglobin levels in stable haemodialysis patients converting from epoetin alpha/beta.
    Bock HA; Hirt-Minkowski P; Brünisholz M; Keusch G; Rey S; von Albertini B;
    Nephrol Dial Transplant; 2008 Jan; 23(1):301-8. PubMed ID: 17890745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immediate pain sensation is less with subcutaneous epoietin-beta compared to subcutaneous darbepoietin-alpha.
    Ter Wee PM; de Koter Y; van der Veer O; van Vliet MH
    Clin Nephrol; 2009 Sep; 72(3):177-80. PubMed ID: 19761721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Resistance index to epoetin alpha and to darbepoetin-alpha in chronic hemodialysis patients: a cohort study].
    Pérez-García R; Rodríguez Benítez P; Jofre R; López-Gómez JM; Villaverde MT; Blanco A; Blanco S; Sánchez M
    Nefrologia; 2007; 27(3):340-9. PubMed ID: 17725454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term intravenous epoetin-alpha / darbepoetin-alpha ratio in iron-replete hemodialysis patients.
    Icardi A; Sacco P; Salvatore F; Romano U
    J Nephrol; 2007; 20(1):73-9. PubMed ID: 17347977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
    Smith WB; Dowell JA; Pratt RD
    Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erythropoietic agents in anaemic patients with cancer: a retrospective observational survey of epoetin alpha, epoetin beta and darbepoetin alpha use in routine clinical practice.
    Pujade-Lauraine E; Richard AJ; Sapède C; Hayward C
    Oncol Rep; 2005 Oct; 14(4):1037-44. PubMed ID: 16142369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preference for monthly darbepoetin alfa dosing in patients with chronic kidney disease not receiving dialysis.
    Hoggard J; Crouch T; McMurray S; Levine M; Prathikanti R; Scarlata D; Audhya P
    Curr Med Res Opin; 2006 Oct; 22(10):2023-30. PubMed ID: 17022861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Change of EPO treatment from subcutaneous epoetin to intravenous epoetin or darbepoetin alpha].
    Molina M; García Hernández MA; Navarro MJ; De Gracia MC; Ortuño T
    Nefrologia; 2004; 24(6):564-71. PubMed ID: 15683029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients.
    Nissenson AR; Swan SK; Lindberg JS; Soroka SD; Beatey R; Wang C; Picarello N; McDermott-Vitak A; Maroni BJ
    Am J Kidney Dis; 2002 Jul; 40(1):110-8. PubMed ID: 12087568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the pharmacokinetics of two recombinant human erythropoietin preparations: epoetin zeta and epoetin alfa. 2nd Communication: A monocentric, double-blind, randomized, single dose, three-period crossover trial in healthy volunteers.
    Kirkov V; Dimitrova V; Siebert-Weigel M; Wolf-Pflugmann M; Koytchev R; Richter W; Bronn A; Arsova S; Kromminga A
    Arzneimittelforschung; 2008; 58(5):220-4. PubMed ID: 18589556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost comparison of epoetin alpha, epoetin beta and darbepoetin alpha for cancer patients with anaemia in the clinical practice setting.
    Reichardt B
    J Clin Pharm Ther; 2006 Oct; 31(5):503-12. PubMed ID: 16958829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer.
    Schwartzberg LS; Yee LK; Senecal FM; Charu V; Tomita D; Wallace J; Rossi G
    Oncologist; 2004; 9(6):696-707. PubMed ID: 15561813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A retrospective cohort study to assess the impact of therapeutic substitution of darbepoetin alfa for epoetin alfa in anemic patients with myelodysplastic syndrome.
    Patton JF; Sullivan T; Mun Y; Reeves T; Rossi G; Wallace JF
    J Support Oncol; 2005; 3(6):419-26. PubMed ID: 16350429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.